InflaRx (NASDAQ:IFRX) Rating Increased to Hold at Wall Street Zen

Key Points

• Wall Street Zen upgraded InflaRx from a “sell” to a “hold” rating, adding to a mixed but generally positive analyst backdrop that includes a consensus rating of “Moderate Buy” and a $5.80 price target.
• The stock traded down 2.6% and opened at $2.58, while still sitting above its 52-week low of $0.71 and below its 52-week high of $2.95.
• InflaRx beat earnings expectations in its latest quarterly report, posting a loss of $0.09 per share versus the expected $0.17 loss, though revenue remained minimal at $0.01 million.

InflaRx (NASDAQ:IFRX - Get Free Report) was upgraded by equities research analysts at Wall Street Zen from a "sell" rating to a "hold" rating in a report issued on Saturday.

IFRX has been the topic of several other reports. Guggenheim reissued a "buy" rating and issued a $14.00 target price on shares of InflaRx in a report on Tuesday, April 21st. Weiss Ratings reissued a "sell (d-)" rating on shares of InflaRx in a research report on Friday, March 27th. Finally, Oppenheimer began coverage on InflaRx in a research report on Friday, April 24th. They issued an "outperform" rating and a $5.00 target price on the stock. Four research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $5.80.

InflaRx Trading Down 2.6%

InflaRx stock opened at $2.58 on Friday. The business's fifty day simple moving average is $1.19 and its two-hundred day simple moving average is $1.13. InflaRx has a 12 month low of $0.71 and a 12 month high of $2.95. The company has a market capitalization of $186.51 million, a price-to-earnings ratio of -3.63 and a beta of 2.42.

InflaRx (NASDAQ:IFRX - Get Free Report) last released its earnings results on Thursday, May 7th. The company reported ($0.09) EPS for the quarter, topping the consensus estimate of ($0.17) by $0.08. The company had revenue of $0.01 million during the quarter, compared to the consensus estimate of $0.01 million. On average, equities research analysts predict that InflaRx will post -0.59 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the stock. Cubist Systematic Strategies LLC raised its stake in shares of InflaRx by 33.9% in the first quarter. Cubist Systematic Strategies LLC now owns 30,053 shares of the company's stock worth $31,000 after buying an additional 7,616 shares during the period. HRT Financial LP bought a new position in shares of InflaRx in the fourth quarter worth about $47,000. Concurrent Investment Advisors LLC raised its stake in shares of InflaRx by 56.9% in the fourth quarter. Concurrent Investment Advisors LLC now owns 52,951 shares of the company's stock worth $53,000 after buying an additional 19,200 shares during the period. Insigneo Advisory Services LLC bought a new position in shares of InflaRx in the fourth quarter worth about $61,000. Finally, Quadrature Capital Ltd bought a new position in shares of InflaRx in the fourth quarter worth about $104,000. Institutional investors own 42.39% of the company's stock.

InflaRx Company Profile

InflaRx N.V. is a clinical‐stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapies targeting the complement system, with an emphasis on the complement‐1a (C5a) pathway. The company's lead product candidate, vilobelimab (IFX‐1), is a monoclonal antibody designed to selectively inhibit C5a, a potent pro‐inflammatory peptide implicated in a range of autoimmune and inflammatory diseases. InflaRx seeks to address high‐unmet medical needs by advancing treatments for conditions such as hidradenitis suppurativa, pyoderma gangrenosum and other rare and severe inflammatory disorders.

Vilobelimab has been evaluated in multiple Phase II trials, demonstrating proof of concept in reducing key inflammatory markers and improving clinical outcomes.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.